Transvascular Approach May Reduce Pain, Improve QOL in Pancreatic Cancer
Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.
APN Highlights Pain/Symptom Management Strategies for GI Cancer
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Inavolisib-Based Therapy Boosts Progression-Free Survival in Breast Cancer
Inavolisib-based therapy reaches the primary end point of the phase 3 INAVO120 study among patients with PIK3CA-mutated breast cancer.
The Importance of Proactive End-of-Life Discussions in Oncology
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Rolling NDA Completed for Avutometinib Combo in Ovarian Cancer Subtype
An FDA filing decision is anticipated before the end of 2024 for avutometinib/defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer.
Managing Toxicities Following BCMA-Directed Immunotherapy for Myeloma
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
Atezolizumab/Matched-Targeted Therapy Improves OS in Anaplastic Thyroid Cancer
Patients with anaplastic thyroid cancer had a significant boost to overall survival with atezolizumab and targeted therapy.
BCMA Serum Displays Monitoring Advantages vs Conventional Biomarkers
BCMA testing tracks clinical changes faster without the need for marker expression vs monoclonal immunoglobulin, a conventional multiple myeloma marker.
BCMA Levels Shown to Predict Multiple Myeloma Risk, Severity, and Response
Studies indicate that higher BCMA levels are associated with a greater need for therapy years following diagnosis for patients with smoldering myeloma.
Study Shows Post-Mastectomy Disparities in Breast Cancer Minority Groups
Findings speak to the need of cultural, racial, and ethnic inclusion when designing breast cancer trials and developing patient-reported outcome measures.
Perioperative Chemo/IO Yields Promise as Long-Term Treatment for NSCLC
Patients with non–small cell lung cancer had a positive long-term benefit with perioperative chemoimmunotherapy, according to the 5-year NADIM trial update.
Comfort in Whole-Body MRI Testing May Ease Anxiety in LFS Population
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Affirming the Feasibility of cfDNA Sequencing Use in Li-Fraumeni Syndrome
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
Approaching End-of-Life Discussions With Directness and Compassion
Kelley A. Rone, DNP, RN, AGNP-c, highlights how to best approach end-of-life discussions with patients receiving treatment for cancer.
Uproleselan Combo Does Not Improve EFS Vs Chemo in Newly Diagnosed AML
Investigators will present topline data from the phase 2/3 study of uproleselan/chemotherapy at a future medical meeting.
Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases
Two cases of patients with multiple myeloma and kidney failure successfully underwent CAR T-cell therapy using ciltacabtagene autoleucel.
Vascular biomarkers reveal a unique toxicity profile of posttransplant cyclophosphamide: secondary analysis of BMT CTN 0402 and 1202
Posttransplant cyclophosphamide leads to unique changes in vascular biomarkers, revealing a distinct toxicity profile compared to other GVHD prophylaxis regimens.
Serum BCMA May Help Predict Outcomes, Monitor Disease in Multiple Myeloma
James R. Berenson, MD, discusses serum BCMA and markers for predicting outcomes and monitoring disease in patients with multiple myeloma.
Letter from Rigel Points to New Safety Signal of Pralsetinib in RET+ NSCLC
Data from the AcceleRET-Lung trial show an imbalanced risk of severe and fatal infection with pralsetinib for patients with RET fusion-positive NSCLC.
cfDNA Sequencing May Show Cancer Detection Benefits in Li-Fraumeni Syndrome
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
FDA Grants Accelerated Approval to Asciminib in Ph+ CML in Chronic Phase
Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.
HERC Tool Demonstrates Feasibility in Advancing Equitable Cancer Care
Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.
FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications
The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.
Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status
Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.
STX-478 Yields Efficacy, Tolerability in PI3K-Mutated Advanced Solid Tumors
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 May Show Preferential Binding in PI3K-Mutated Solid Tumors
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer
Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.
The Evolving Landscape of Prostate Cancer Management
Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.
Empowering Awareness to Address Rising Gynecological Cancer Incidence
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Different Treatment Algorithms for Gastric Cancers May Improve Outcomes
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.